Anika Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $16.86
- Today's High:
- $17.48
- Open Price:
- $17.21
- 52W Low:
- $19.9508
- 52W High:
- $32.51
- Prev. Close:
- $17.24
- Volume:
- 239450
Company Statistics
- Market Cap.:
- $378.54 million
- Book Value:
- 19.507
- Revenue TTM:
- $152.44 million
- Operating Margin TTM:
- -11.65%
- Gross Profit TTM:
- $91.85 million
- Profit Margin:
- -10.33%
- Return on Assets TTM:
- -3.17%
- Return on Equity TTM:
- -5.48%
Company Profile
Anika Therapeutics Inc had its IPO on 1993-04-29 under the ticker symbol ANIK.
The company operates in the Healthcare sector and Medical Devices industry. Anika Therapeutics Inc has a staff strength of 297 employees.
Stock update
Shares of Anika Therapeutics Inc opened at $17.21 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $16.86 - $17.48, and closed at $17.05.
This is a -1.1% slip from the previous day's closing price.
A total volume of 239,450 shares were traded at the close of the day’s session.
In the last one week, shares of Anika Therapeutics Inc have slipped by -5.38%.
Anika Therapeutics Inc's Key Ratios
Anika Therapeutics Inc has a market cap of $378.54 million, indicating a price to book ratio of 1.571 and a price to sales ratio of 2.8101.
In the last 12-months Anika Therapeutics Inc’s revenue was $152.44 million with a gross profit of $91.85 million and an EBITDA of $-3214000. The EBITDA ratio measures Anika Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Anika Therapeutics Inc’s operating margin was -11.65% while its return on assets stood at -3.17% with a return of equity of -5.48%.
In Q3, Anika Therapeutics Inc’s quarterly earnings growth was a negative -50.5% while revenue growth was a positive 1.8%.
Anika Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 78.7402
- Trailing PE
- 0
- PEG
- 3.1868
Its diluted EPS in the last 12-months stands at $-1.08 per share while it has a forward price to earnings multiple of 78.7402 and a PEG multiple of 3.1868. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Anika Therapeutics Inc’s profitability.
Anika Therapeutics Inc stock is trading at a EV to sales ratio of 2.5648 and a EV to EBITDA ratio of -60.3346. Its price to sales ratio in the trailing 12-months stood at 2.8101.
Anika Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $347.75 million
- Total Liabilities
- $26.35 million
- Operating Cash Flow
- $-1691000.00
- Capital Expenditure
- $3.02 million
- Dividend Payout Ratio
- 0%
Anika Therapeutics Inc ended 2025 with $347.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $347.75 million while shareholder equity stood at $284.94 million.
Anika Therapeutics Inc ended 2025 with $6.80 million in deferred long-term liabilities, $26.35 million in other current liabilities, 146000.00 in common stock, $215.63 million in retained earnings and $6.72 million in goodwill. Its cash balance stood at $87.78 million and cash and short-term investments were $87.78 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Anika Therapeutics Inc’s total current assets stands at $167.76 million while long-term investments were $0 and short-term investments were $34.17 million. Its net receivables were $34.17 million compared to accounts payable of $8.35 million and inventory worth $37.24 million.
In 2025, Anika Therapeutics Inc's operating cash flow was $-1691000.00 while its capital expenditure stood at $3.02 million.
Comparatively, Anika Therapeutics Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $17.05
- 52-Week High
- $32.51
- 52-Week Low
- $19.9508
- Analyst Target Price
- $35.33
Anika Therapeutics Inc stock is currently trading at $17.05 per share. It touched a 52-week high of $32.51 and a 52-week low of $32.51. Analysts tracking the stock have a 12-month average target price of $35.33.
Its 50-day moving average was $21.42 and 200-day moving average was $26.75 The short ratio stood at 7.99 indicating a short percent outstanding of 0%.
Around 193.4% of the company’s stock are held by insiders while 9131.6% are held by institutions.
Frequently Asked Questions About Anika Therapeutics Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company’s non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.